Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518878-14-01

Enrollment

1261

Registered

2024-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease, Rheumatic disease, Oncology

Brief summary

Numer of infusion related reactions, Grade of IRR

Detailed description

Efficacy treatment parameters (progression, remission), plasma levels of the administered drug, Patient reported expierence measurements, number of treatments needed, death, switchting of treatmet

Interventions

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGRemicade 100 mg powder for concentrate for solution for infusion.

DRUGHerceptin 150 mg powder for concentrate for solution for infusion

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGVectibix 20 mg/ml concentrate for solution for infusion

DRUGEntyvio 300 mg powder for concentrate for solution for infusion

DRUGTruxima 500 mg concentrate for solution for infusion

DRUGTecentriq 1 875 mg solution for injection

DRUGYERVOY 5 mg/ml concentrate for solution for infusion

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGPerjeta 420 mg concentrate for solution for infusion

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Numer of infusion related reactions, Grade of IRR	—

Secondary

Measure	Time frame
Efficacy treatment parameters (progression, remission), plasma levels of the administered drug, Patient reported expierence measurements, number of treatments needed, death, switchting of treatmet	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026